Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Proof-of-concept studies in vitro and in animal models demonstrated bNAbs' ability to block viral entry into cells, suppress viremia and reduce cell-associated viral DNA. Combination bNAbs were more effective than single bNAb in suppressing viremia. When bNAb was used with ART with or without combination latency reversing agents, it prevented viral rebound after ART interruption in at least half of the animals. In one study, macaques with low baseline viral load achieved viral remission even after the blood bNAb titer was no longer detected. SUMMARY: The acute HIV infection period represents a unique opportunity to explore the use of bNAbs with ART to limit the reservoir seeding that may enhance the chance of HIV remission. This article discusses the effects of early ART and bNAbs on HIV reservoirs and proposes research strategies in acute HIV infection aiming at HIV reservoir reduction and HIV remission.
|
Authors | Jintanat Ananworanich, Brian McSteen, Merlin L Robb |
Journal | Current opinion in HIV and AIDS
(Curr Opin HIV AIDS)
Vol. 10
Issue 3
Pg. 198-206
(May 2015)
ISSN: 1746-6318 [Electronic] United States |
PMID | 25700203
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Chemical References |
- Anti-Retroviral Agents
- Antibodies, Neutralizing
- HIV Antibodies
|
Topics |
- Animals
- Anti-Retroviral Agents
- Antibodies, Neutralizing
(immunology)
- CD4-Positive T-Lymphocytes
- HIV Antibodies
(immunology)
- HIV Infections
(immunology, virology)
- HIV-1
(immunology)
- Humans
- Mice
|